Hoping for October baseball for the @Orioles next year!

Thanks Sam, interesting point about the LDL-C baseline being quite low. Still, wouldn't the FOURIER (O'Donoghue et al) data indicate oppty for MACE reduction even when LDL-C is well-controlled? ahajournals.org/doi/10.1161/…

Re: #2, the O'Donoghue analysis of the FOURIER trial shows residual benefit from lower Lp(a) even when LDL is well-controlled. As Sam pointed out, the LDL-C in HORIZON may have been even lower, but that is a matter of degree, not that there is no benefit from Lp(a) lowering. ahajournals.org/doi/10.1161/…

$amlx great comeback story. I hope they come back to ALS at some point!

Remarkable data for kids with SCD and B-thal. nejm.org/doi/full/10.1056/NE…

jamanetwork.com/journals/jam… Dropoff in overall Rx is not surprising given it's curative but this has still been a massive class of drugs over the past ~12 years and the public health impact isn't discussed enough.

Worth remembering this molecule is a macrocyclic peptide with a 37-member ring. Impressive work by Merck’s process chemists.

Nice review article on Lp(a) jamanetwork.com/journals/jam…

Amazingly, much of this (excellent) empirical research was PREDICTED by a mathematical model of Huntington Dz onset from way back in 2007!! The observation that HTT homozygotes have similar age of onset as hets led to concept of a CAG length threshold. pmc.ncbi.nlm.nih.gov/article…